***Borrelia miyamotoi* disease (BMD): Neither Lyme disease nor relapsing fever**

Sam R. Telford III [1], Heidi K. Goethert [1,2], Philip Molloy [2], Victor Berardi [2], Hanumara Ram Chowdri [3], Joseph L. Gugliotta [4], Timothy J. Lepore [5]

1. Tufts University, Cummings School of Veterinary Medicine, North Grafton, MA
2. Imugen, Inc., Norwood, MA
3. Hawthorn Medical Associates, and South Coast Hospital System, New Bedford, MA
4. Hunterdon Medical Center, Flemington, NJ
5. Nantucket Cottage Hospital, Nantucket, MA

sam.telford@tufts.edu

heidi.goethert@tufts.edu

pmolloy@imugen.com

vberardi@imugen.com

hchowdri@hawthornmed.com

Gugliotta.Joseph@hunterdonhealthcare.org

tjalepore@hotmail.com

Corresponding Author: Sam R. Telford III ScD, Tufts University, Dept of Infectious Disease and Global Health, 200 Westboro Rd, North Grafton, MA 01536; telephone 508-887-4236
sam.telford@tufts.edu

Key Words:

Borrelia miyamotoi; Lyme disease; deer ticks; borreliosis; zoonotic infection

Synopsis: *Borrelia miyamotoi* disease (BMD) is a newly recognized borreliosis globally transmitted by ticks of the *Ixodes persulcatus* species complex. Once considered to be a tick symbiont with no public health implications, *B. miyamotoi* is increasingly being recognized as the agent of a nonspecific febrile illness often misdiagnosed as acute Lyme disease without rash, or as ehrlichiosis. The frequency of its diagnosis in the northeastern U.S. is similar to that of HGA. A diagnosis of BMD may be confirmed by PCR analysis of acute blood samples, or by

seroconversion using a recombinant GlpQ enzyme immunoassay. As with Lyme disease or HGA, BMD is successfully treated with oral doxycycline or amoxicillin.

Key Points:

- *Borrelia miyamotoi* was first described from Japanese *Ixodes persulcatus* ticks. Subsequently, it was detected as an inherited infection of *I. dammini* ticks in the northeastern United States.
- The index case of *B. miyamotoi* disease (BMD) in the United States comprised meningoencephalitis in an elderly immunocompromised patient. BMD is likely a common, underdiagnosed zoonosis wherever Lyme disease is reported.
- Cases typically present with headache, fever, chills, fatigue, and myalgia.
- BMD should not be considered a relapsing fever; there is no crisis with rigors or hyperpyrexia followed by diaphoresis and hypotension.
- BMD may be confirmed by PCR of acute blood samples or by seroconversion to a recombinant GlpQ antigen.
- Treatment is identical to that for Lyme disease.

Introduction

Tick borne *Borrelia* spp. are now usually divided into two taxonomic groups, which correspond to the typical human disease manifestations, Lyme disease or relapsing fever, as well as to their tick vectors, prostriate ixodid ticks and argasid ticks, respectively (Table 1). Arnold Theiler (1904) demonstrated spirochetes in metastriate ixodid ticks infesting African cattle with a mild disease that was called “tick spirochetosis” or bovine borreliosis. *Borrelia theileri* subsequently has been globally reported, usually associated with cattle and their cosmopolitan tick *Rhipicephalus* (*Boophilus*) *microplus* and *R. annulatus*. Professor Kenji Miyamoto of

Asahikawa Medical College, during 1990-1992, isolated spirochetes from *I. persulcatus* ticks collected in Hokkaido, Japan. These isolates were subsequently demonstrated by analysis of the 23S-5S rDNA and other genes, to be a new species related to the relapsing fever spirochetes (Fukunaga et al. 1995). The name *Borrelia miyamotoi* was applied to this new species, and subsequently, this spirochete has been detected wherever *I. persulcatus* species complex ticks (*I. dammini*, *I. scapularis*, *I. pacificus*, *I. ricinus*, herein referred to as *Ixodes* spp.) occur. In 1995, borreliae from American Lone Star ticks (*Amblyomma americanum*) were identified independently by two research groups (Armstrong et al. 1996; Barbour et al. 1996) and provided the names *B. lonestari* and *B. barbouri*; the former name has prevailed in the literature.¹ Molecular phylogenetic analyses demonstrate that *B. theileri*, *B. lonestari*, and *B. miyamotoi* comprise a group together, deep within the relapsing fever spirochete clade (Barbour 2014) and not within the other ixodid (“hard”) tick maintained borreliae, namely those in *Ixodes* spp. that are recognized as *B. burgdorferi* sensu lato. Although phylogenetically considered to be relapsing fever spirochetes, the metastriate-transmitted *Borrelia* spp. should not be assumed to be biologically similar to the true relapsing fever spirochetes maintained by argasid (“soft”) ticks, nor to cause typical relapsing fever.

As with *B. burgdorferi* (see reviews in this issue), evidence is emerging that *B. miyamotoi* comprises a species complex or group of genospecies (Barbour 2014) and should be referred to as *B. miyamotoi* sensu lato. Asian, European, and American clades are apparent with phylogenetic analyses of typical gene targets such as flagellin (Figure 1). Unlike *B. burgdorferi* s.l., for which less than half of the recognized genospecies have been associated with human

¹ The name *B. lonestari* technically should be presented in quotation marks or referred to as *Candidatus Borrelia lonestari*, inasmuch as the requirements for naming a new bacterial taxon have not been fulfilled, in particular, formal publication in the IJSEM and its propagation *in vitro* that would enable deposition of cultures into an accepted biological repository.

infection, all three *B. miyamotoi* clades recognized thus far have been associated with human clinical cases.

The biology of *B. theileri* has been well studied, particularly clinical aspects of bovine borreliosis (Callow 1967) and vector-pathogen interactions (Smith et al. 1985). “*Borrelia lonestari*” has been circumstantially associated with a disease manifesting mainly as erythema migrans (Southern Tick Associated Rash Illness [STARI] or Masters Disease), but its formal incrimination as the etiologic agent remains lacking (Feder et al. 2013). Further discussion of STARI/Masters Disease as a borreliosis is beyond the scope of this review. *B. miyamotoi*, despite its global distribution in Lyme disease vectors, remained as an incidental finding in field surveys and was thought to be an endosymbiont of *Ixodes* spp. ticks. In 2011, a case series comprising febrile Russian patients, some with a recurrent fever, was presented with polymerase chain reaction (PCR) evidence that implicated *B. miyamotoi* as the etiologic agent (Platonov et al. 2011). This was the first suggestion that *B. miyamotoi* was capable of causing human disease, and was followed in 2013 by the index case for North America (Gugliotta et al. 2013) and soon thereafter that for the European Union (Hovius et al. 2013). We now know that at least in the northeastern U.S., *B. miyamotoi* disease (BMD) may be relatively common (Molloy et al. in press).

Epidemiology

BMD appears to be a common infection in sites that are intensely zoonotic for Lyme disease. For the Russian case-series, BMD was diagnosed as frequently as tick borne encephalitis (TBE) and about half as frequently as erythema migrans due to *B. burgdorferi* s.l. (Platonov et al. 2011). Active case detection using PCR of acute phase blood samples from

11,515 febrile patients in southern New England demonstrated that 3.1% had evidence of infection by *Babesia microti*, 1.4% by *Anaplasma phagocytophilum*, and 0.8% by *B. miyamotoi* (Molloy et al. in press). It should be noted that blood was sampled only from patients whose signs and symptoms were sufficient to cause them to seek medical attention; it is likely that subclinical *B. miyamotoi* infections occur. Indeed, an enzyme immunoassay using the recombinant *B. miyamotoi* antigen GlpQ (rGlpQ), suggested that the serum of about 4% of participants from cross sectional serosurveys in New England Lyme disease endemic sites was reactive; about 9% of these sera reacted to antigens of *B. burgdorferi* (Krause et al. 2014).

The Russian case series presented from May-August (Platonov et al. 2011), had an estimated 12-16 day incubation period. Adult *I. persulcatus*, the Lyme disease and TBE vector in the Yekaterinburg area, seek hosts during May and June (Fillipova 1985), with nymphs and larvae appearing during June and activity extending into August. It is thus not clear which *I. persulcatus* developmental stage transmits *B. miyamotoi* to people in Russia. In southern New England, about 70% of all the BMD cases were diagnosed during July and August (Molloy et al. in press), which incriminates larval *I. dammini* as the main BMD vector because nymphal *I. dammini* have their main period of activity during May to mid-July. Two-thirds of all Lyme disease cases in the northeastern U.S. are reported during June and July (Bacon et al. 2008), which demonstrates that nymphal *I. dammini* are the main vector stage. Accordingly, BMD in the northeastern U.S. has a different epidemiologic pattern than does Lyme disease. Education about preventing Lyme disease typically focuses on temporal risk during early summer (June) and with the emergence of adult deer ticks during the fall (October-November). Larval deer ticks would be found in the same habitats as nymphs or adults, but would require more intimate contact with the ground and leaf litter for a person to become infested. As with Lyme disease,

nymphal and adult *Ixodes* spp. may transmit infection, with prevalence rates of *B. miyamotoi* infection typically ranging from 1%-10% (Scoles et al. 2001; Richter et al. 2003; Mun et al. 2006; Ogden et al. 2011). However, for most tick borne infections, an infected tick is a necessary but insufficient condition for risk: risk is instead determined by whether a tick is allowed to feed for an extended duration. Adult *Ixodes* spp. tend to seek hosts during the colder months when people are dressed in a manner that inhibits tick attachment. Adults are also much bigger and more easily detected and removed. Nymphal *Ixodes* spp. are empirically very efficient vectors for Lyme disease, and the finding that more BMD cases coincide with the larval tick season of activity in the northeastern U.S. suggests that nymphs may not transmit *B. miyamotoi* as efficiently as do larvae.

As with *B. burgdorferi* s.l., diverse kinds of warm-blooded animals may serve as amplifying hosts for *B. miyamotoi*. *B. miyamotoi* is easily propagated in the laboratory in both sigmondontine and murine rodents (Scoles et al. 2001). A common reservoir host for *B. burgdorferi* in the eastern U.S., the white footed mouse (*Peromyscus leucopus*), is naturally infected by *B. miyamotoi* (Barbour et al. 2009). European and Japanese rodents known to maintain *B. burgdorferi* s.l. are also competent hosts for *B. miyamotoi* (Taylor et al. 2013; Burri et al. 2014). *B. miyamotoi* has been detected in blood or in ticks removed from passerine or galliform birds (Hamer et al. 2012) as well as from ticks attached to deer (although it is not clear whether the tick was infected prior to infesting the deer or acquired infection from the deer). Whether specific vertebrate reservoirs are required for *B. miyamotoi* perpetuation is not axiomatic.

Transmission

B. miyamotoi was first isolated from host seeking, unfed adult *I. persulcatus* ticks (Fukunaga et al. 1995), which implied that spirochetes had been maintained through the molt from fed nymph to adult stage ticks (*i.e.*, transstadial transmission). The comprehensive report that established the endemicity of *B. miyamotoi* in North America (Scoles et al 2001) confirmed transstadial transmission as well as by inheritance (*i.e.*, transovarial transmission). *B. burgdorferi* s.l., in contrast, is inefficiently inherited, if at all (Rollend et al. 2013), while the classic relapsing fever spirochetes (e.g., *B. hermsi*, *B. turicata*, *B. crocidurae*, *B. duttoni*) can be readily maintained by this mode of transmission, at least for as many as 5 generations (Burgdorfer and Varma 1967). Vertebrate hosts can serve to increase the prevalence of infection in the general tick population, and may even be required to maintain full pathogenicity. However, they may not be necessary for spirochetal persistence from generation to generation. The agent of bovine borreliosis, *B. theileri*, is also maintained in this manner, although the hard ticks that transmit *B. theileri*, *Rhipicephalus microplus*, are “one host” ticks which (unlike most ticks that detach after each bloodmeal) attach as larvae, feed and quickly develop into nymphs and then adults in situ without leaving the individual host. *B. lonestari* is found in host-seeking larval *Amblyomma americanum* (Telford, unpublished) and is likely to have inheritance as an important mode of perpetuation. Thus, the metastriate hard tick borreliae (*B. theileri*, *B. lonestari*, and *B. miyamotoi*) share aspects of the biology of the soft tick-transmitted relapsing fever spirochetes.

Although *B. burgdorferi* s.l. requires reactivation within the feeding *Ixodes* spp. prior to attaining infectivity, the true relapsing fever spirochetes apparently do not; isolates are readily made by homogenizing and injecting infected soft ticks into mice. Reactivation was first

described for *Rickettsia rickettsii*, the agent of Rocky Mountain spotted fever (Spencer and Parker 1923). Host seeking wood ticks, *Dermacentor andersoni*, collected from zoonotic sites failed to induce productive infection in guinea pigs when homogenized and intraperitoneally injected, but those that were allowed to pre-feed for 24 hours on uninfected animals, then homogenized and injected into uninfected guinea pigs induced a typical fatal infection. Heating ticks to 37C for several hours also induced the activation of the dormant rickettsiae, as demonstrated by their capacity to cause lethal infection. Subsequently, virtually all hard tick-transmitted pathogens were recognized to require a similar reactivation to attain infectivity (Katavolos et al. 1998). The molecular basis of reactivation has been elegantly studied in *B. burgdorferi* s.l. (Rosa et al. 2005) and is the reason for the minimum 24 hour delay between tick attachment and delivery of an infectious dose to initiate Lyme disease. Reactivation does not seem to occur with the soft tick-transmitted relapsing fever spirochetes, perhaps because soft ticks require only a few hours for feeding, in contrast to hard ticks, which require days. It is not known whether *B. miyamotoi* requires reactivation during transmission by *Ixodes* spp. Accordingly, it is not clear whether prompt removal of feeding ticks may reduce the risk of acquiring BMD, as it does Lyme disease, although prompt removal might influence the quantum of infection (dose) delivered.

Because *B. miyamotoi* causes spirochetemia and can be detected by PCR in acute blood samples of febrile individuals, it is possible that transfusion-transmitted cases will be described. Further supporting this possibility is the finding that, infected mouse blood retains infectivity by syringe passage under storage conditions that are similar to those used in blood banking (Krause et al. 2015). On the other hand, the capacity of *B. miyamotoi* to persist in people who have recovered from acute illness remains unknown.

Clinical presentation

The BMD index cases in North America (Gugliotta et al. 2013) and in the European Union. (Hovius et al 2013) presented with meningoencephalitis. Both patients were elderly and had recently undergone chemotherapy for malignancy. BMD in both of these individuals was progressive, comprising memory and cognitive deficits, and spirochetes were detected in cerebrospinal fluid samples, demonstrating active intrathecal infection. For both patients, acute disease was entirely resolved following antibiotic treatment. How frequently *B. miyamotoi* breaches the blood-brain barrier of otherwise healthy individuals remains to be determined, though in our large case series no sign of meningeal irritation or encephalitis was observed (Molloy et al. in press)..

In the Russian case series described above (Platonov et al. 2011), it was noted that BMD generally presented with more systemic signs and symptoms, particularly headache and fever, compared to Lyme disease. Virtually all patients presented with fever (axillary temperature >37.2C), fatigue, and headache, a statistically significant difference from the presentation of Lyme disease patients. The next most common signs and symptoms were myalgia, chills, nausea and arthralgia, characterizing 30%-60% of the patients. Similarly, a series of PCR positive patients from New England (Molloy et al. in press) almost always demonstrated fever, chills, headache, myalgia and fatigue. Referring physicians often noted that patients with BMD exhibited more significant symptoms than patients with Lyme disease. In fact, BMD can be misdiagnosed as ehrlichiosis due to *A. phagocytophilum* or Ehrlichia spp. (Chowdri et al. 2014). In both case series, rashes were observed for fewer than 10% of the patients.

Although recurrent fever has been reported from as many as 10% of the Russian and American BMD cases, classical relapsing fever is a very different disease clinically and biologically. Relapsing fever has a sudden onset of two or more episodes of high fever (*i.e.*, >39C), with an inter-febrile period of a few days. The fevers end with half an hour of rigors, hyperpyrexia, and hypertension followed by hours of diaphoresis and hypotension. Often the patient is also delirious during this period. The spleen is enlarged and jaundice may be apparent in these patients (Southern and Sanford 1969). In most respects, relapsing fever is a very severe, acute disease compared to either BMD or Lyme disease. With respect to pathobiology, relapsing fever spirochetes are characterized by their evasion of the host immune response by antigenic variation (Barbour 1987), with progressive replacement of dozens of variable membrane proteins (VMPs). No evidence has been presented to suggest the phenomenon of antigenic variation by *B. miyamotoi*. Accordingly, even though *B. miyamotoi* is phylogenetically a relapsing fever spirochete, BMD should not be considered relapsing fever.

We present 3 case vignettes, representing the spectrum of BMD that we have observed.

Case 1. Uncomplicated BMD.

In late November, an active 70 year old woman from southeastern Massachusetts presented to an urgent care center with 2 days of fever to 38.9C, shaking chills, rigors and headache. She denied nausea, vomiting, diarrhea or upper respiratory symptoms. A “big” tick had been imbedded in her flank two weeks prior. Her past medical history was significant for hypertension, hyperlipidemia, reflux disease and osteopenia. Blood was drawn and she was advised to take nonsteroidal anti-inflammatory drugs (NSAIDs), rest, and hydrate. Here

complete blood cell count (CBC) was normal and a rapid influenza test was negative. PCR demonstrated *B. miyamotoi* DNA in the blood sample and 5 days after the initial presentation, the patient reported symptomatic improvement with the use of NSAIDs without antimicrobials. Her body aches and chills resolved, and the patient was otherwise well, but she continued to complain of residual fatigue. Skin examination revealed residual erythema at the site of the tick bite but no other rashes. She was started on doxycycline 100mg twice daily and a repeat blood sample taken at this time was negative for *B. miyamotoi* or other deer tick-borne infections. She was re-evaluated in late December after completion of the doxycycline course and complained of residual fatigue. She was seen again in late January feeling much better with her fatigue resolving.

Case 2. Human anaplasmosis or BMD?

A healthy 57 year old woman from southeastern Massachusetts became acutely ill in early August with fevers and chills, headache, joint and muscle pain. Two days after onset, she went to the community hospital emergency room due to increasing lethargy, where she was found to be febrile to 38.9C and tachycardic (HR = 116). She reported a tick bite three weeks prior. Peripheral blood smears, blood and urine cultures were negative and her CSF was normal. A CBC revealed a white blood cell (WBC) count of 7,600 with 71% polymorphonuclear leukocytes and 16% neutrophils, a platelet count of 120,000 cells/ μ l and elevated liver transaminases. The patient's chest x-ray was normal, however she was admitted due to her septic appearance, and human anaplasmosis was presumptively diagnosed based on the clinical presentation and lab data. She was hydrated with IV fluids and started on IV doxycycline. A CBC the next day revealed WBC 6,200 and platelets of 80,000 cells/ μ l. She improved within 24 hours and although her headaches persisted, she was discharged on oral doxycycline.

Blood taken prior to treatment was positive by PCR for *B. miyamotoi* and negative for both *A. phagocytophilum* and *B. microti*. At her outpatient follow-up, the patient stated that

although her fever resolved within 24 hours of the IV doxycycline, she continued to have fatigue and headaches, unrelieved by oxycodone with acetaminophen. She was alert and oriented but complained of severe headache. Vital signs and physical exam were normal. She was advised to continue doxycycline for a period of three weeks and was given a prescription for butalbital/acetaminophen and caffeine for her headaches. She was re-evaluated 9 days later and all of her symptoms had resolved, including the headaches. A CBC drawn at that time showed a WBC 11,200/uL, HCT 42.8% and PLT 397,000/uL. She has since remained well and is back to her normal activities.

Case 3. Recurrent fever presentation.

A 57 year old female nurse from southeastern Massachusetts felt ill at the end of July with generalized malaise and body aches. She is an avid gardener and has dogs, but did not recall any tick bites. None of her family members had been ill. Her past medical history is significant for hypertension and anxiety. She developed fevers, shaking chills, night sweats and headaches and was evaluated in a local community hospital emergency room where she was given 2 liters of IV fluids and sent home. She continued to be febrile with nausea, fatigue and body aches and went to her primary care physician a few days later. A CBC demonstrated leukopenia and elevated transaminases. She gave a history of allergy to amoxicillin and tetracycline and was sent home without treatment. A whole blood specimen was negative by PCR for *B. microti* and *A. phagocytophilum*, but serum was reactive for IgM-class antibodies to *B. burgdorferi* using a whole cell sonicate EIA, although confirmatory testing by immunoblot was negative. She continued to feel poorly with recurrent fever, chills and headaches associated

with anorexia and weight loss. She had multiple visits to her primary care provider, who continued to monitor her clinically with serial CBCs. No specific diagnosis was made.

Due to persistent symptoms, including fever, generalized arthralgias, malaise, headaches, nausea and loss of appetite, the patient was examined by an infectious disease specialist approximately 5-6 weeks after her initial presentation. She stated her fevers resolved for several days and then relapsed, causing a recurrence of her symptom complex. Physical examination revealed an alert but pale and ill looking woman. All other systems were unaffected and the patient was started on doxycycline while awaiting the results of the lab tests.

Blood samples drawn on 8/2 and 8/30 yielded evidence of *B. miyamotoi* DNA. She was re-evaluated on 9/27; the fever, headache and joint pain had all resolved. She complained of extreme fatigue and the inability to function at her normal pace. Her exam at that visit was normal and her CBC had returned to normal values. She was advised to complete the 4 weeks of doxycycline given that she was able to tolerate it with no side effects. The patient called the office on Oct 16 stating all of her symptoms had resolved and she was feeling markedly better.

Diagnosis

If Lyme disease is known to be zoonotic where the patient may have acquired infection, BMD is also likely to be endemic and thus should be considered in the differential diagnosis for a febrile, tick-exposed patient. As with the other deer tick-transmitted infections (*i.e.*, Lyme disease, babesiosis, HGA, or Powassan/deer tick virus fever), patients with BMD present with an undifferentiated febrile illness, which may include acute headaches, fever, chills, myalgia, arthralgia, fatigue, or malaise. BMD patients often appear septic and laboratory studies reveal

leukopenia, thrombocytopenia, and elevated transaminases. Such findings, along with clinical presentation, usually requires providers to exclude HGA.

Specialized laboratory testing, particularly PCR testing of blood samples collected during acute infection and ideally prior to initiation of treatment, is useful for confirming a BMD diagnosis. Acute anticoagulated blood samples (EDTA or citrate, not heparin) taken prior to treatment may be analyzed for evidence of *B. miyamotoi* DNA by PCR. Commercial testing laboratories are increasingly offering specific PCR testing for *B. miyamotoi*, but physicians need to consider a clinical laboratory experience's with PCR in general when interpreting results. Like all other PCR assays, the failure to detect specific DNA or RNA in the blood does not exclude the possibility of BMD. In addition to *B. burgdorferi*, concurrent infections with *B. microti*, *A. phagocytophilum*, or even deer tick virus are possible and should be ruled out.

Serology is a useful complementary method to PCR for confirming a BMD diagnosis (Molloy et al. in press). Importantly, the recommended two-tiered serologic protocol (Wormser et al. 2006) for confirming a *B. burgdorferi* infection (EIA followed by immunoblot of reactive samples) is not useful for diagnosis of BMD. However, 23% of acute and 90% of convalescent sera from PCR confirmed BMD cases were reactive for IgM antibodies to *B. burgdorferi* using a sonicate antigen EIA. Few of these reactives were considered positive when immunoblots are interpreted as recommended (MMWR 1995). No more than 20% of convalescent BMD sera were reactive in the IgG EIA and of these, only 7% were confirmed by immunoblot. Thus, an IgM reactive sample by Lyme ELISA, but not confirmed by immunoblot, may represent a response to *B. miyamotoi* instead of *B. burgdorferi*. Convalescent sera from BMD patients rarely demonstrate IgG reactivity to *B. burgdorferi* antigens.

The *B. burgdorferi* EIA, when reactive for IgM but not confirmed for specific reactivity, may be effectively complemented by an EIA using a recombinant glycerophosphodiester phosphodiesterase (GlpQ) protein. GlpQ is a 39-42kDa protein that was identified by screening a *B. hermsi* genomic library with high titered human sera collected from a patient with relapsing fever. GlpQ was demonstrated in all *Borrelia* spp. examined except for *B. burgdorferi* s.l., thus allowing for serologic discrimination of relapsing fever from Lyme disease (Schwan et al. 1996). Over 90% of convalescent sera from relapsing fever cases were reactive in EIAs using the recombinant GlpQ (rGlpQ) protein, but none were reactive from either Lyme disease or syphilis cases. Given that *B. miyamotoi* is more closely related to relapsing fever spirochetes than to *B. burgdorferi* s.l., GlpQ was a natural target to serve as the basis for the development of an immunoassay to confirm a diagnosis of BMD.

The rGlpQ EIA appears to be sensitive and specific for confirming BMD (Molloy et al. in press). Lyme disease patient sera did not react with rGlpQ, nor did those from HGA or monocytic ehrlichiosis patients. A low frequency (14%) of IgM reactivity was observed with *B. microti* patient sera; the biologic basis for this finding remains unexplored. Some (3.6%) serum samples from 250 healthy individuals residing west of the Mississippi River were considered IgG reactive; this puzzling finding may reflect exposure to relapsing fever spirochetes other than *B. miyamotoi*. Although *GlpQ* homologs may be found in *Haemophilus influenzae* and even *Escherichia coli*, their sequences are divergent enough so that crossreactivity with *B. miyamotoi* GlpQ is not likely (Krause et al. 2014). Of a well-studied BMD case series, 86% were considered to have seroconverted to rGlpQ (Molloy et al. in press); convalescent sera comprised those taken at least 5 days after initial presentation.

The need for a recombinant protein antigen was determined by the lack of availability of whole cell *B. miyamotoi* antigens. Although the Japanese *B. miyamotoi* type strain HT31 was originally isolated in BSK II medium and apparently can be productively maintained *in vitro*, until very recently no one has succeeded in culturing the American or Eurasian strains. The only means of propagating these other strains has been by serial blood passage in SCID mice. These immunodeficient mice sustain spirochetemias approaching 1000-5000 bacteria/mL for long durations, and they are very useful in making primary isolates by inoculating blood from BMD patients. However, the cost of purchasing SCID mice and maintaining them for the purpose of harvesting spirochetes for use as serologic reagents would be prohibitive. HT31 itself is not available through ATCC or other biological repositories and must be requested from a handful of research laboratories within the U.S. or Europe.

Successful cultivation of *B. miyamotoi* has recently been reported (Wagemakers et al. 2014; Margos et al. 2015). Both research groups report passaging HT31 and a North American *B. miyamotoi* strain in variants of Kelly-Pettenkofer medium (Kelly's medium is the base for BSK II medium, which is used to cultivate *B. burgdorferi*). In one system, 10% fetal calf serum and slight modifications of the concentrations of bovine serum albumin, CMRL-1066 base, HEPES, glucose, and rabbit serum allowed for propagation within standard conditions used for *B. burgdorferi*. In the other system, the critical factors included 50% fetal calf serum in a 6% carbon dioxide atmosphere. In both systems, cell densities did not exceed 10^7 bacteria/mL, whereas *B. burgdorferi* in BSK II medium will attain densities of 10^9 cells/mL (Barbour 1985). Both research groups report failing to maintain *B. miyamotoi* viability in unmodified BSKII medium but Fukunaga et al. (1996) originally propagated HT31 in BSKII medium to densities sufficient to harvest cells for preparing immunoblots or DNA for southern blots or pulse field gel

electrophoresis. It may be that the 3 members of *B. miyamotoi* s.l. may differ in their in vitro growth requirements, or that batches of BSK vary with respect to their capacity to sustain HT31 growth. In any event, the possibility of propagating *B. miyamotoi* in vitro allows for generating more traditional serologic reagents such as whole cell sonicate EIAs and immunoblots.

SCID mice could be inoculated with acute blood samples and borreliae may be visualized by peripheral blood smears of the mice 7-14 days after inoculation (Figure 2). The sensitivity of this procedure has not yet been determined and this method would be restricted to a limited number of research laboratories. Spirochetes were demonstrable in the CSF of the American and European index cases, but these were unusual findings in elderly immunocompromised individuals. However, because *B. miyamotoi* causes peripheral blood spirochetemia, Giemsa stained blood smears made from acute blood samples may allow for a microscopic confirmation of the diagnosis. Thick smears, as performed for malaria diagnosis, are the most likely method for successful detection; by quantitative PCR, a range of 5-53,000 (mean 8313) spirochetes were estimated per milliliter of whole blood from our recent case series (Molloy et al., in press). For comparison, the sensitivity of thick blood smears for malarial parasites is approximately 15,000 infected red blood cells per milliliter (Bruce Chwatt 1985).

In summary, BMD should be considered in febrile patients from Lyme-endemic regions of the northeast United States, who present between April to November with evidence of a systemic illness or who appear septic. Other infections to be considered in these patients include Lyme disease without rash, babesiosis, HGA, deer tick virus fever and West Nile fever. Elevated transaminases, leukopenia, and thrombocytopenia narrow the list of deer tick transmitted infections to BMD and HGA; in sites with dog ticks or Lone Star ticks, rickettsiosis, monocytic ehrlichiosis, and tularemia may also be considered. PCR testing of an acute, pre-

treatment blood sample for *Borrelia* spp. (“pan-borrelia”), preferably followed by a species specific PCR assay as a confirmatory identification, is the most efficient way to demonstrate active infection. As with Lyme disease or virtually any other tick-transmitted infection, acute serology for BMD is not sensitive, but it is useful as an archived comparison to a convalescent sample collected 3 to 4 weeks later. BMD convalescent serum is usually IgM reactive in *B. burgdorferi* EIA (whole cell sonicate), but the confirmatory Lyme immunoblot using the two-tiered protocol will not be interpreted as positive. Only a fifth of convalescent BMD patient sera will react in the *B. burgdorferi* IgG EIA (and usually are negative by the confirmatory immunoblot), but more than 80% will react in the rGlpQ EIA for IgG. Hence, the confirmation of BMD rests on elevated transaminases, acute blood PCR, and seroconversion to rGlpQ.

Treatment

It is very likely that BMD has been occurring in Lyme-endemic sites from the very beginning of our recognition of Lyme disease as an American zoonosis, but presumptively has been diagnosed as atypical Lyme disease and treated successfully on that basis. Oral doxycycline (100 mg twice a day for 10-21 days) or amoxicillin (500 mg three times a day for 14-21 days) as currently recommended for early disseminated Lyme disease (Wormser et al. 2006) has been sufficient to treat BMD (Molloy et al. in press). Treatment failure has not been documented. The clinical implications of milder infections and failure to treat remains undetermined; mild or subclinical infections clearly occur given the evidence for 5%-10% prior exposure in New England communities suggested by cross-sectional serosurveys (Krause et al. 2014). The manner in which BMD presents in children remains to be described.

Prevention would be as for any other tick borne infection, namely personal protection using repellents such as DEET, clothing treatment with permethrin, daily showers, tick checks, prompt tick removal, and vigilance for unexplained fevers when living in or visiting Lyme-endemic sites.

Self-Assessment

1. A patient presents during July with a 4 day history of fever, headache, myalgias, arthralgias, and fatigue. Labs are normal. The patient lives in a Lyme disease endemic site and states that he frequently finds ticks on his dog. No rash is evident. Lyme disease is suspected and an ELISA screen for antibody to *Borrelia burgdorferi* is ordered. The ELISA is positive for IgM but not IgG; the IgM immunoblot confirmation test is negative, with only 2 of the 3 required bands observed. The health care provider can conclude which of the following:

- a. The patient likely has Lyme disease but the antibody response has not fully developed.
- b. The patient does not have Lyme disease because the immunoblot was negative.
- c. The patient may have either Lyme disease or BMD, or both.
- d. Convalescent serology is indicated; the patient is treated presumptively for Lyme disease.

2. The physician diagnoses the patient in (1) as having early Lyme disease and treats accordingly. The patient returns because he continues to experience fatigue and headache even after completing the first week of amoxicillin. The most appropriate followup would be:

- a. PCR testing for *Borrelia miyamotoi*.
- b. Changing treatment to doxycycline.
- c. PCR testing for *Anaplasma phagocytophilum* and *Babesia microti*.
- d. Consider the IgM ELISA a false positive, stop the antibiotics, and suggest supportive care for undifferentiated viral illness.

3. You have been asked to speak in a public forum on preventing Lyme disease. You state that personal protection, such as repellents and tick checks, should be used from Memorial Day to Labor Day. The state public health epidemiologist demurs, saying that the months of greatest risk are June and July, and that repellent use is not without possible side effects. You justify your answer by:

- a. Noting that we need to take a wholistic approach to preventing vector borne infections and that mosquito transmitted infections are most common in August and September. Deer ticks and dog ticks are most common in June and July. Thus, repellent use should be encouraged throughout the summer.
- b. Agreeing that the months of greatest risk for Lyme disease are indeed June and July, but that some nymphal deer ticks are present in late May and even as late as August in most sites; and, that BMD may be transmitted by larvae, which are most common from July through September.
- c. Stating that people are most active outdoors in Lyme endemic sites from Memorial Day to Labor Day and that any outdoor activity in sites where ticks are common should prompt personal protective efforts.
- d. Disagreeing with the statement that repellent use is not without side effects; billions of doses of DEET have been applied with fewer than a few dozen known adverse events. The benefit of using repellent as directed by the product label far outweighs the small likelihood of harm due to the repellent itself.

4. You see a patient with a 2 year history of nonspecific signs and symptoms, mainly fatigue and arthralgia. She has lived until recently in Manhattan, and admits to little outdoor activity. She has been diagnosed elsewhere with chronic Lyme disease and *Bartonella* coinfection, based on serologic testing at a specialty laboratory in California, and has been taking oral antibiotics for 7 months with no improvement. She requests PCR testing for BMD because she believes it could be yet another co-infection that is causing her illness. Your most appropriate action is:

- a. Agree to evaluate her for BMD, because relatively little is known about this newly recognized infection.
- b. Decline to order either PCR or serology for BMD, noting that all current information suggests that BMD is adequately treated using the typical regimens for Lyme disease and that there is no evidence for chronic sequelae.
- c. Inform her that her illness cannot be BMD because some authorities suggest that *B. miyamotoi* causes relapsing fever, and she does not report this.
- d. Suggest that she have a general health workup because her diagnosis of chronic Lyme disease with co-infection may be erroneous and is preventing the identification of other treatable conditions.

5. A patient who recently vacationed in northwest Wisconsin acutely presents with severe headache, fever, chills, and myalgia. The headache does not abate with OTC analgesics. His CBC demonstrates leucopenia with left shift. Transaminases are slightly elevated. You suspect ehrlichiosis and presumptively treat with doxycycline. The headache and fever disappear 12 hours after the first 100mg dose of doxycycline. The patient returns for a followup visit in 10 days, and a blood sample is drawn. The transaminases remain slightly elevated but the patient

reports a full recovery. Serologies for specific antibody to *Anaplasma phagocytophilum* and *Ehrlichia muris* are negative. You should consider:

- a. The possibility that your ehrlichiosis diagnosis was incorrect, and order rGlpQ serology for BMD, as well as Lyme disease serology.
- b. Nothing further. The patient was treated and reports full recovery. Confirming the diagnosis would only be useful for epidemiologic surveillance.
- c. PCR and serologic testing for subclinical *Babesia microti* infection because the patient is an avid blood donor and was very likely exposed to deer ticks; doxycycline would not have eliminated this protozoan and thus he might be a risk to the blood supply.
- d. Nothing further: serology for confirming *Anaplasma phagocytophilum* infection can be insensitive and prompt treatment may have blunted the antibody response.

ANSWERS

Answer 1: A, C, and D are acceptable.

Answer 2: C

Answer 3: ALL are correct.

Answer 4: Either B or D.

Answer 5: Best answers are B or D, however C might also be considered.

References

1. Theiler A. Spirillosis of cattle. J Comp Pathol 1904; 17:47-55.
2. Fukunaga M, Takahashi Y, Tsuruta Y, et al. Genetic and phenotypic analysis of *Borrelia miyamotoi* sp. nov., isolated from the ixodid tick *Ixodes persulcatus*, the vector for Lyme disease in Japan. International Journal Of Systematic Bacteriology 1995;45:804-810.
3. Armstrong PM, Rich SM, Smith RD, Hartl DL, Spielman A, Telford SR III. A new *Borrelia* infecting Lone Star ticks. Lancet 1996; 347:67-68
4. Barbour AG, Maupin GO, Teltow GJ, Carter CJ, Piesman J. Identification of an uncultivable *Borrelia* species in the hard tick, *Amblyomma americanum*. J Infect Dis 1996; 173:403-409.
5. Barbour AG. Phylogeny of a relapsing fever *Borrelia* species transmitted by the hard tick *Ixodes scapularis*. Infect Genet Evol. 2014; 27:551-8
6. Callow LL. Observations on tick-transmitted spirochaetes of cattle in Australia and South Africa. British Veterinary Journal 1967;123:492-7
7. Smith RD, Miranpuri GS, Adams JH, Ahrens EH. *Borrelia theileri*: Isolation from ticks (*Boophilus microplus*) and tick-borne transmission between splenectomized calves. American Journal Of Veterinary Research 1985;46:1396-1398.
8. Feder HM Jr, Hoss DM, Zemel L, Telford SR 3rd, Dias F, Wormser GP. Southern Tick-Associated Rash Illness (STARI) in the North: STARI following a tick bite in Long Island, New York.. Clin Infect Dis. 2011; 53:e142-146
9. Platonov AE, Karan LS, Kolyasnikova NM, Makhneva NA, Toporkova MG, Maleev VV, et al. Humans infected with relapsing fever spirochete *Borrelia miyamotoi*, Russia. Emerging Infectious Diseases 2011;17:1816-1823.

10. Gugliotta JL, Goethert HK, Berardi VP, Telford SR. Meningoencephalitis from *Borrelia miyamotoi* in an immunocompromised patient. *NEJM* 2013; 368:240-245.
11. Hovius JWR, de Wever B, Sohne M, Brouwer MC, Coumou J, Wagemakers A, et al. A case of meningoencephalitis by the relapsing fever spirochete *Borrelia miyamotoi* in Europe. *Lancet* 2013; 382:658.
12. Molloy PJ, Telford SR, Chowdri HR, Lepore TJ, Gugliotta JL, Weeks KE, Hewins ME, Goethert HK, Berardi VP. *Borrelia miyamotoi* disease in the northeastern United States: a case series. *Ann Intern Med*, in press
13. Krause PJ, Narasimhan S, Wormser GP, Barbour AG, Platonov AE, et al. *Borrelia miyamotoi* sensu lato seroreactivity and seroprevalence in the northeastern United States. *Emerg Infect Dis* 2014; 20:1183-1190
14. Fillipova NA. Taiga Tick: *Ixodes persulcatus* Schulze (Acarina: Ixodidae). Nauka Publishers, Leningrad, 1985. 416pp.
15. Bacon RM, Kugeler KJ, Mead PS. Surveillance for Lyme disease – United States, 1992-2006. *MMWR* 2008; 57(SS10):1-9
16. Scoles GA, Papero MA, Beati L, Fish D. A relapsing fever group spirochete transmitted by *Ixodes scapularis* ticks. *Vector Borne Zoonotic Diseases* 2001; 1: 21-34
17. Richter D, Schlee DB, Matuschka FR. Relapsing fever-like spirochetes infecting European vector tick of Lyme disease agent. *Emerging Infectious Diseases* 2003;9:697-701.
18. Mun J, Eisen RJ, Eisen L, Lane RS. Detection of a *Borrelia miyamotoi* sensu lato relapsing-fever group Spirochete from *Ixodes pacificus* in California. *Journal Of Medical Entomology* 2006;43:120-123.

19. Ogden NH, Margos G, Aanensen DM, et al. Investigation of genotypes of *Borrelia burgdorferi* in *Ixodes scapularis* ticks collected during surveillance in Canada. *Applied And Environmental Microbiology* 2011;77:3244-3254.
20. Barbour AG, Bunikis J, Travinsky B, Hoen AG, Diuk-Wasser MA, Fish D, et al. Niche partitioning of *Borrelia burgdorferi* and *Borrelia miyamotoi* in the same tick vector and mammalian reservoir species. *American Journal Of Tropical Medicine And Hygiene* 2009;81:1120-1131
21. Burri C, Schumann O, Schumann C, Gern L. Are *Apodemus* spp. mice and *Myodes glareolus* reservoirs for *Borrelia miyamotoi*, *Candidatus Neoehrlichia mikurensis*, *Rickettsia helvetica*, *R. monacensis* and *Anaplasma phagocytophilum*? *Ticks Tick Borne Dis.* 2014;5:245-51.
22. Taylor KR, Takano A, Konnai S, Shimozuru M, Kawabata H, Tsubota T. *Borrelia miyamotoi* infections among wild rodents show age and month independence and correlation with *Ixodes persulcatus* larval attachment in Hokkaido, Japan. *Vector Borne Zoonotic Dis.* 2013;13:92-7.
23. Hamer SA, Hickling GJ, Keith R, Sidge JL, Walker ED, Tsao JI. Associations of passerine birds, rabbits, and ticks with *Borrelia miyamotoi* and *Borrelia andersonii* in Michigan, U.S.A. *Parasit Vectors.* 2012;5:231.
24. Rollend L, Fish D, Childs JE. Transovarial transmission of *Borrelia* spirochetes by *Ixodes scapularis*: a summary of the literature and recent observations. *Ticks Tick Borne Dis.* 2013; 4:46-51.
25. Burgdorfer W, Varma MGR. Transstadial and transovarial development of disease agents in arthropods. *Annu Rev Entomol* 1967; 12:347-376.

26. Spencer RR, ParkerRR. Rocky Mountain spotted fever: infectivity of fasting and recently fed ticks. *Publ Health Rep* 1923; 38:333-
27. Katavolos P, Armstrong PM, Dawson JE, Telford SR III. Duration of tick attachment required for transmission of human granulocytic ehrlichiosis. *J. Infect. Dis.* 1998; 177: 1422-1425
28. Rosa PA, Tilly K, Stewart PE. The burgeoning molecular genetics of the Lyme disease spirochaete. *Nat Rev Microbiol.* 2005;3:129-43
29. Krause PJ, Hendrickson JE, Steeves TK, Fish D. Blood transfusion transmission of the tick-borne relapsing fever spirochete *Borrelia miyamotoi* in mice. *Transfusion.* 2015;55:593-7
30. Chowdri HR, Gugliotta JL, Berardi VP, Goethert HK, Molloy PJ, Sterling SL, Telford SR. *Borrelia miyamotoi* infection presenting as human granulocytic anaplasmosis: a case report. *Ann Intern Med.* 2013;159:21-7. doi: 10.7326/0003-4819-159-1-201307020-00005.
31. Southern P, Sanford J. Relapsing fever. A clinical and microbiological review. *Medicine* 1969;48:129-149.
32. Barbour AG. Immunobiology of relapsing fever. *Contrib Microbiol Immunol* 1987; 8: 125-127.
33. Paddock CD, Telford SR. Through a glass, darkly: global incidence of tick borne diseases. Pp 1-41 in *Critical Needs and Gaps in Understanding Prevention, Amelioration, and Resolution of Lyme and Other Tick-Borne Diseases: The Short-Term and Long-Term Outcomes - Workshop Report.* Institute of Medicine, National Academy of Sciences, 2011.
34. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and

babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43:1089-1134

35. Centers for Disease Control and Prevention. Recommendations for test performance from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR 1995; 44:590-591.

36. Schwan TG, Schrumpf ME, Hinnebusch BJ, Anderson DE, Konkel ME. GlpQ: an antigen for serological discrimination between relapsing fever and Lyme borreliosis. J Clin Microbiol. 1996; 34: 2483–2492

37. Wagemakers A, Oei A, Fikrig MM, Miellel WR, Hovius JW The relapsing fever spirochete *Borrelia miyamotoi* is cultivable in a modified Kelly-Pettenkofer medium, and is resistant to human complement. Parasit Vectors. 2014; 7: 418.

38. Margos G, Stockmeier S, Hizo-Teufel C, Hepner S, Fish D, Dautel H, Sing A, Dzaferovic E, Rieger M, Jungnick S, Binder K, Straubinger RK, Fingerle V. Long-term in vitro cultivation of *Borrelia miyamotoi*. Ticks Tick Borne Dis. 2015;6:181-4.

39. Bruce Chwatt LJ. Essential Malariology, 2nd Edition. John Wiley and Sons, NY, 1985. 452 pp.

40. Pollack RJ, Telford SR III, Spielman A. Standardisation of a complex medium for the growth of *Borrelia burgdorferi*. J. Clin. Microbiol. 1993; 31:1251-1255

41. Telford SR, Goethert HK. Emerging and emergent tick borne infections. Pp344-376 in Ticks: Biology, Disease and Control, eds Chappell LH, Bowman AS, Nuttall PA. Cambridge University Press, 2008.

POTENTIAL CONFLICTS OF INTEREST. VPB is an associate director of laboratory science and CEO of Imugen, Inc. PJM and HKG are employees of Imugen, Inc. HRC is a clinical consultant and SRT is a consultant and scientific advisor to Imugen, Inc.

ACKNOWLEDGMENTS. SRT and HKG are supported, in part, by grants from the National Institutes of Health (U01AI109656, R41AI078631); the Tufts Innovation Institute; the Evelyn Lilly Lutz Foundation; the Dorothy Harrison Egan Foundation; and the Bill and Melinda Gates Foundation.

Table 1. Kinds of ticks and their roles as vectors of *Borrelia* spp.

Family	Subfamily	Colloquial name	Species example	Common name	Associated <i>Borrelia</i> sp.
Argasidae	Argasinae	Soft ticks	<i>Ornithodoros moubata</i>	Tampan tick	<i>B. duttoni</i>
Ixodidae	(division Prostriaata) -- Ixodinae	Hard ticks	<i>Ixodes persulcatus</i>	Taiga tick	<i>B. burgdorferi</i> s.l., <i>B. miyamotoi</i> s.l.
Ixodidae	(division Metastriata) -- Rhipicephalinae, Amblyomminae, Haemaphysalinae, Hyalomminae	Hard ticks	<i>Amblyomma americanum</i>	Lone Star tick	<i>B. lonestari</i>

Figure 1. Phylogenetic relationship of *B. miyamotoi* s.l. Neighbor-joining analysis of a 608 bp portion of the flagellin gene. Numbers at nodes represent proportion of 1000 bootstrap replicates consistent with the branching topology; branch lengths are proportional to nucleotide differences. Three *B. miyamotoi* clades are apparent: American, Japanese/Russian and European.

(Data from GenBank; Available at: <http://www.ncbi.nlm.nih.gov/genbank/>)

Figure 2. Giemsa stained (pH 7.0) thin blood smear of blood from a CB17-SCID mouse concurrently infected by *Babesia microti* and *Borrelia miyamotoi*. Three spirochetes are seen in this field. X630, bright field illumination.